Therefore, coadministration of antioxidant GSH and the P-gp inhibitor Tet with L-dopa appears to be an ideal solution, not only for the etiology of PD but also due to the possible involvement of oxidative neurotoxicity in long-term L-dopa treatment. Here, PGP is linked to Parkinson disease.